Lifecore Biomedical, Inc.
LFCR
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $165.0M
$4.40
▲ +1.15%
P/E
-4.78
Mkt Cap
$165.0M
52-Wk Range
$3.63–$8.98
52-Week Range
$3.63 - $8.98
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized expertise in pharmaceutical-grade sodium hyaluronate manufacturing with established market presence
- Integrated CDMO capabilities offering full-service development from formulation through clinical production
- Diversified revenue streams reducing dependence on single market segment
- Established relationships with pharmaceutical partners requiring specialized injectable manufacturing
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Increasing demand for injectable therapeutics in orthopedic and ophthalmic markets
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Falling
-21.0% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying LFCR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 2, 2026
AUG 5, 2026
Reported EPS of -$0.19 vs -$0.19 consensus (0.0% surprise). Revenue of $34.2M vs $34.2M expected (-0.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
+8%
-2%
-4%
+26%
+36%
-34%
-16%
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
Q4 26
$24.7M
$32.6M
$35.2M
$36.4M
$31.1M
$44.4M
$23.2M
$30.8M
Margins · last 8Q
Gross
40.5%
Operating
13.5%
Profit
7.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Barrington · $6.00 · Apr 29, 2026
vs Industry
How LFCR stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related